Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 11:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 81 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Test Result Management Clear all
Completed Not applicable Interventional Results available

A Pilot Trial to Test the Feasibility of Utilizing Home Blood Pressure Monitoring to Optimize the Administration of Midodrine Among Decompensated Cirrhosis Patients

NCT05928624
View directory record Official record
Conditions
Cirrhosis, Liver, Portal Hypertension, Ascites Hepatic
Interventions
Withings Home Blood Pressure Device and Scale, Standard of Care
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Oct 31, 2026, 11:44 AM EDT
Recruiting Not applicable Interventional

An Adjunct Test Distinguishing Bacterial From Viral Etiology Improves Resource Utilization and Efficiency in the ED.

NCT06070688
View directory record Official record
Conditions
Respiratory Tract Infections
Interventions
MeMed BV® biomarker test, Usual care
Diagnostic Test
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 31, 2026, 11:44 AM EDT
Completed Not applicable Interventional

Diagnostic Algorithm in Suspected Upper Extremity Deep Vein Thrombosis

NCT01324037
View directory record Official record
Conditions
Suspected Upper Extremity Deep Vein Thrombosis
Interventions
diagnostic algorithm
Other
Lead sponsor
University Medical Center Groningen
Other
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Oct 31, 2026, 11:44 AM EDT
Completed Phase 3 Interventional Results available

Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness

NCT03137992
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Placebo, Test Product (tiotropium bromide inhalation powder), Reference Product (Spiriva®)
Drug
Lead sponsor
Lupin, Inc.
Industry
Eligibility
40 Years and older
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
34
States / cities
Andalusia, Alabama • Jasper, Alabama • Glendale, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Oct 31, 2026, 11:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Bioavailability Study of Lisinopril Tablets, 10 mg

NCT01375244
View directory record Official record
Conditions
Healthy
Interventions
Lisinopril, Zestril
Drug
Lead sponsor
Par Pharmaceutical, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 17, 2011 · Synced Oct 31, 2026, 11:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study in Healthy People to Test How 2 Different Formulations of BI 695501 Are Taken up by the Body When Given as an Injection

NCT05203289
View directory record Official record
Conditions
Healthy
Interventions
BI 695501 - higher concentration, BI 695501 - lower concentration
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 55 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Miami, Florida • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 31, 2026, 11:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Immediate v. Delayed CT/NG Test for Treatment in the ED

NCT01989130
View directory record Official record
Conditions
Reproductive Tract Infections
Interventions
Roche AMPLICOR CT/NG, Cepheid Xpert CT/NG Test
Device
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 31, 2026, 11:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Administration Method of Cognitive Screening in Older Individuals With Hearing Loss

NCT03402932
View directory record Official record
Conditions
Hearing Loss, Sensorineural, Cognitive Impairment
Interventions
Auditory amplified, Visual, Auditory unamplified
Other
Lead sponsor
Northwestern University
Other
Eligibility
60 Years to 85 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 31, 2026, 11:44 AM EDT
Terminated Not applicable Interventional Results available

Test to Determine the Effectiveness of Moisturizing Balm Used on Babies With Dry, Itchy Skin

NCT02404493
View directory record Official record
Conditions
Eczema
Interventions
EpiCeram Skin Barrier Emulsion, 1% Colloidal Oatmeal Balm
Device · Drug
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
6 Months to 47 Months
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 31, 2026, 11:44 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)

NCT01618669
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
Regadenoson, Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)
Drug · Procedure
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
60
States / cities
Mobile, Alabama • Fremont, California • Long Beach, California + 52 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 31, 2026, 11:44 AM EDT
Completed Phase 1 Interventional

A Study to Test How Zongertinib is Taken up in the Blood of People With and Without Liver Problems

NCT06692322
View directory record Official record
Conditions
Liver Diseases, Healthy
Interventions
Zongertinib (BI 1810631)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 31, 2026, 11:44 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Test 2 Treat: Can we Improve the Testing and Treatment of High Cholesterol in Patients Who Have Been Hospitalized for a Cardiac Event by Providing Education to Doctors and Patients?

NCT06471036
View directory record Official record
Conditions
ASCVD, LDL-C
Interventions
Care Champion Intervention
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 31, 2026, 11:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study To Test How Filgrastim Hospira Works In The Body Of Healthy Study Subjects When Given By Subcutaneous Injection (Shot) Compared To An Already U.S.-Approved Drug Neupogen® (Amgen)

NCT02766647
View directory record Official record
Conditions
Neutropenia (Low White Blood Cell Count)
Interventions
Filgrastim Hospira (US), US-approved Neupogen®
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 10, 2016 · Synced Oct 31, 2026, 11:44 AM EDT
Recruiting Not applicable Interventional

IBS Skin Patch Test Food Allergy Study

NCT06288672
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
True avoidance diet, Sham avoidance diet
Other
Lead sponsor
IBS-80, LLC
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
North Wales, Pennsylvania • Barboursville, West Virginia
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 31, 2026, 11:44 AM EDT
Completed Not applicable Interventional

Evaluating Home Testing Devices for the Management of Glaucoma

NCT05325996
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
Standard Automatic Perimetry Humphrey Field Analyzer, visuALL H, iCare Home Tonometer, Spectralis Optical coherence tomography (OCT)
Diagnostic Test
Lead sponsor
Wills Eye
Other
Eligibility
20 Years to 80 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 31, 2026, 11:44 AM EDT
Not yet recruiting Phase 2 Interventional

Herbal Supplement (Biocidin REMOVE) for Bacterial Overgrowth in Irritable Bowel Syndrome

NCT07768267
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS), Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
Interventions
Biocidin REMOVE, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 31, 2026, 11:44 AM EDT
Completed Phase 2 Interventional Results available

Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection

NCT00918281
View directory record Official record
Conditions
Solid Tumors, High Grade Gliomas, Lung Cancer, Head and Neck Cancer, Sarcoma, Renal Cell Carcinoma, Breast Cancer
Interventions
Fluciclatide Injection
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 31, 2026, 11:44 AM EDT
Completed No phase listed Observational

Comparing Program Options for Latinos With Diabetes

NCT03004664
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Support Empowerment Model, The Chronic Care Model
Behavioral
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Oct 31, 2026, 11:44 AM EDT
Completed Not applicable Interventional

A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)

NCT01542866
View directory record Official record
Conditions
Age Related Macular Degeneration (AMD)
Interventions
Health Management Tool (HMT)
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
23
States / cities
Beverly Hills, California • Sacramento, California • Torrance, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 31, 2026, 11:44 AM EDT
Completed Phase 2 Interventional Results available

A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations

NCT02962960
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Anifrolumab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Thousand Oaks, California • Orlando, Florida • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 31, 2026, 11:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy Subjects

NCT02823171
View directory record Official record
Conditions
Healthy
Interventions
Treatment A: 400 mg Pacritinib P3CT, Treatment B: 400 mg of pacritinib FMI
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 31, 2026, 11:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, and PK of Fulvestrant After IM Administration

NCT03324061
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Fulvestrant for Injectable Suspension, Faslodex (Reference)
Drug
Lead sponsor
Eagle Pharmaceuticals, Inc.
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
12
States / cities
Long Beach, California • DeLand, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 31, 2026, 11:44 AM EDT
Completed Not applicable Interventional

Caregiver Implementation Strategies Field Pre-Test

NCT06770036
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder Symptoms
Interventions
Implementation Resource Package for Caregivers
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
4 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 31, 2026, 11:44 AM EDT
Not listed Not applicable Interventional

Immunosuppression Management in Renal Transplant Recipients With Transplant Excellence Based on TruGraf Test

NCT04670926
View directory record Official record
Conditions
Kidney Transplant Rejection, Immunosuppression
Interventions
TruGraf, Standard of Care
Diagnostic Test · Other
Lead sponsor
Transplant Genomics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2021 · Synced Oct 31, 2026, 11:44 AM EDT